Your browser doesn't support javascript.
loading
The structure and function of YTHDF epitranscriptomic m6A readers.
Sikorski, Vilbert; Selberg, Simona; Lalowski, Maciej; Karelson, Mati; Kankuri, Esko.
Afiliação
  • Sikorski V; Faculty of Medicine, Department of Pharmacology, University of Helsinki, Finland.
  • Selberg S; Institute of Chemistry, University of Tartu, Tartu, Estonia.
  • Lalowski M; Helsinki Institute of Life Science (HiLIFE), Meilahti Clinical Proteomics Core Facility, Department of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Gene Expression, Institute of Molecular Biology and Biotechnology, Faculty of B
  • Karelson M; Institute of Chemistry, University of Tartu, Tartu, Estonia.
  • Kankuri E; Faculty of Medicine, Department of Pharmacology, University of Helsinki, Finland. Electronic address: esko.kankuri@helsinki.fi.
Trends Pharmacol Sci ; 44(6): 335-353, 2023 06.
Article em En | MEDLINE | ID: mdl-37069041
ABSTRACT
Specific RNA sequences modified by a methylated adenosine, N6-methyladenosine (m6A), contribute to the post-transcriptional regulation of gene expression. The quantity of m6A in RNA is orchestrated by enzymes that write and erase it, while its effects are mediated by proteins that bind to read this modification. Dysfunction of this post-transcriptional regulatory process has been linked to human disease. Although the initial focus has been on pharmacological targeting of the writer and eraser enzymes, interest in the reader proteins has been challenged by a lack of clear understanding of their functional roles and molecular mechanisms of action. Readers of m6A-modified RNA (m6A-RNA) - the YTH (YT521-B homology) domain-containing protein family paralogs 1-3 (YTHDF1-3, referred to here as DF1-DF3) - are emerging as therapeutic targets as their links to pathological processes such as cancer and inflammation and their roles in regulating m6A-RNA fate become clear. We provide an updated understanding of the modes of action of DF1-DF3 and review their structures to unlock insights into drug design approaches for DF paralog-selective inhibition.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: RNA / Regulação da Expressão Gênica Limite: Humans Idioma: En Revista: Trends Pharmacol Sci Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Finlândia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: RNA / Regulação da Expressão Gênica Limite: Humans Idioma: En Revista: Trends Pharmacol Sci Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Finlândia